Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASKB589 + CAPOX + Tislelizumab in 1L CLDN18.2+ Gastric/GEJ Adenocarcinoma
NCT06206733Phase 3Active, not recruiting
- Sponsor
- AskGene Pharma
- Start
- Jan 2024
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of ASKB589 in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by AskGene Pharma. Started Jan 2024; status: active, not recruiting.
02
Drugs
ASKB589
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06206733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06206733.